TLR7 and diffuse large B-cell lymphoma: Accordingly, the suppressive ODN HJ901 may target the TLR7/9-mediated signaling pathway and be useful as a novel strategy for treating patients with ABC-DLBCL expressing the MyD88 L265P mutation.